1. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy
   Ping-Lian Yang et al, 2020, Cancers CrossRef
2. Post-Translational Modifications That Drive Prostate Cancer Progression
   Ivana Samaržija, 2021, Biomolecules CrossRef
3. Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
   Yong Jun Lee et al, 2021, Mol.Cells CrossRef
4. Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance
   Cinzia Antognelli et al, 2021, Cancers CrossRef
5. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
   Matteo Landriscina, 0 CrossRef
6. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
   Matteo Landriscina, 0 CrossRef
7. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.
   Matteo Landriscina, 0 CrossRef
8. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.
   Matteo Landriscina, 0 CrossRef
9. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
   Matteo Landriscina, 0 CrossRef
10. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    Matteo Landriscina, 0 CrossRef
11. Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells
    S. González-Ochoa et al, 2022, Journal of Immunology Research CrossRef
12. Hypoxia as a Modulator of Inflammation and Immune Response in Cancer
    Rosa A. Castillo-Rodríguez et al, 2022, Cancers CrossRef
13. Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression
    Amber B. Jones et al, 2022, Cancers CrossRef
14. Emerging Proteins in CRPC: Functional Roles and Clinical Implications
    Piaoping Kong et al, 2022, Front. Oncol. CrossRef
15. The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
    Agnieszka Witalisz-Siepracka et al, 2022, Front. Immunol. CrossRef
16. The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors
    Maria Teresa Palano et al, 2022 CrossRef
17. Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker
    Zhibo He et al, 2023, Sci Rep CrossRef
18. HIF1α-dependent and independent pathways regulate the expression of PD-L1 in prostate cancer
    Erasmia T. Xanthopoulou et al, 2023, Med Oncol CrossRef
19. Astragaloside IV-PESV Repressed T Cell Immunosuppression by Inhibiting PD-L1 Expression in Prostate Cancer through STAT3 Pathway
    Xujun You et al, 2023, Journal of Food Biochemistry CrossRef